Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway

Nature Medicine

Volumn 10, Issue 1, 2004, Pages 80-86

  Yasoda, Akihiro ^a   Komatsu, Yasato ^a   Chusho, Hideki ^a   Miyazawa, Takashi ^a   Ozasa, Ami ^a   Miura, Masako ^a   Kurihara, Tatsuya ^b   Rogi, Tomohiro ^b   Tanaka, Shoji ^b   Suda, Michio ^a   Tamura, Naohisa ^a   Ogawa, Yoshihiro ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUNTORY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC PEPTIDE TYPE C; RECOMBINANT PROTEIN; STAT1 PROTEIN; FGFR3 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN TYROSINE KINASE;

ACHONDROPLASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GROWTH PLATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; ANIMAL; CELL DIVISION; GENETICS; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE;

ANIMALIA;

ACHONDROPLASIA; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CHONDROCYTES; FIBROBLAST GROWTH FACTORS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; NATRIURETIC PEPTIDE, C-TYPE; ORGAN CULTURE TECHNIQUES; PHENOTYPE; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER; TRANSGENES;

EID: 11144358656     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm971     Document Type: Article

References (44)

1. Oberklaid, F., Danks, D.M., Jensen, F., Stace, L. & Rosshandler, S. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J. Med. Genet. 16, 140-146 (1979).
2. Bellus, G.A. et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet. 56,368-373 (1995).
3. Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335-342 (1994).
4. Cohen, M.M. Jr. Short-limb skeletal dysplasias and craniosynostosis: what do they have in common? Pediatr. Radiol. 27, 442-446 (1997).
5. Boilly, B., Vercoutter-Edouart, A.S., Hondermarck, H., Nurcombe, V. & Le Bourhis, X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 11, 295-302 (2000).
6. Sahni, M. et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13, 1361-1366 (1999).
7. Sahni, M., Raz, R., Coffin, J.D., Levy, D. & Basilico, C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128, 2119-2129 (2001).
8. Nakao, K., Ogawa, Y., Suga, S. & Imura, H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J. Hypertens. 10, 907-912 (1992).
9. Nakao, K., Ogawa, Y., Suga, S. & Imura, H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J. Hypertens. 10, 1111-1114 (1992).
10. Garbers, D.L. Guanylate cyclase receptor family. Recent. Prog. Horm. Res. 46, 85-96 (1990).
11. Suda, M. et al. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc. Natl. Acad. Sci. USA 95, 2337-2342 (1998).
12. Yasoda, A. et al. Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J. Biol. Chem. 273, 11695-11700 (1998).
13. Chusho, H. et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc. Natl. Acad. Sci. USA 98, 4016-4021 (2001).
14. Pfeifer, A. et al. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 274, 2082-2086 (1996).
15. Matsukawa, N. et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. USA 96, 7403-7408 (1999).
16. Jaubert, J. et al. Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc. Natl. Acad. Sci. USA 96, 10278-10283 (1999).
17. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal over-growth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12, 390-397 (1996),
18. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).
19. Naski, M.C., Colvin, J.S., Coffin, J.D. & Ornitz, D.M. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977-4988 (1998).
20. Chrisman, T.D. & Garbers, D.L. Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. J. Biol. Chem. 274, 4293-4299 (1999).
21. Suganami, T. et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J. Am. Soc. Nephrol. 12, 2652-2663 (2001).
22. Metsaranta, M. et al. Developmental expression of a type II collagen/β-galactosidase fusion gene in transgenic mice. Dev. Dyn. 204, 202-210 (1995).
23. Toyokuni, S. et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest. 76, 365-374 (1997).
24. Shukunami, C. et al. Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J. Cell. Biol. 133, 457-468 (1996).
25. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
26. Murakami, S., Kan, M., McKeehan, W.L. & de Crombrugghe, B. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA 97, 1113-1118 (2000).
27. Yoon, Y.M. et al. Maintenance of differentiated phenotype of articular chondrocytes by protein kinase C and extracellular signal-regulated protein kinase. J. Biol. Chem. 277, 8412-8420 (2002).
28. Minina, E., Kreschel, C., Naski, M.C., Ornitz, D.M. & Vortkamp, A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev. Cell 3, 439-449 (2002).
29. Noonan, K.J., Leyes, M., Forriol, F. & Canadell, J. Distraction osteogenesis of the lower extremity with use of monolateral external fixation. A study of two hundred and sixty-one femora and tibiae. J. Bone. Joint. Surg. Am. 80, 793-806 (1998).
30. Aldegheri, R. Distraction osteogenesis for lengthening of the tibia in patients who have limb-length discrepancy or short stature. J. Bone. Joint. Surg. Am. 81, 624-634 (1999).
31. Tanaka, H. et al. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. Eur. J. Endocrinol. 138, 275-280 (1998).
32. Kanaka-Gantenbein, C. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton). J. Pediatr. Endocrinol. Metab. 14, 17-26 (2001).
33. Scheven, B.A. & Hamilton, N.J. Longitudinal bone growth in vitro: effects of insulin-like growth factor I and growth hormone. Acta Endocrinol. 124, 602-607 (1991).
34. Dieudonne, S.C. et al. Opposite effects of osteogenic protein and transforming growth factor β on chondrogenesis in cultured long bone rudiments. J. Bone Miner. Res. 9, 771-780 (1994).
35. Coxam, V., Miller, M.A., Bowman, B.M., Qi, D. & Miller, S.C. Insulin-like growth factor 1 and parathyroid hormone effects on the growth of fetal rat metatarsal bones cultured in serum-free medium. Biol. Neonate. 68, 368-376 (1995).
36. Kojima, M., Minamino, N., Kangawa, K. & Matsuo, H. Cloning and sequence analysis of a cDNA encoding a precursor for rat C-type natriuretic peptide (CNP). FEBS Lett. 276, 209-213 (1990).
37. Ogawa, Y. et al. Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): comparison with the human CNP gene (NPPC). Genomics 24, 383-387 (1994).
38. Nakayama, H., Yokoi, H. & Fujita, J. Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 20, 4939 (1992).
39. Yokoi, H. et al. Non-radioisotopic quantitative RT-PCR to detect changes in mRNA levels during early mouse embryo development. Biochem. Biophys. Res. Commun. 195, 769-775 (1993).
40. Liu, W. et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell. Biol. 155, 157-166 (2001).
41. Chusho, H. et al. Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. Endocrinology 141, 3807-3813 (2000).
42. Mericq, V., Uyeda, J.A., Barnes, K.M., De Luca, F. & Baron, J. Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. Pediatr. Res. 47, 189-193 (2000).
43. Bonassar, L.J., Grodzinsky, A.J., Srinivasan, A., Davila, S.G. & Trippel, S.B. Mechanical and physicochemical regulation of the action of insulin-like growth factor-I on articular cartilage. Arch. Biochem. Biophys. 379, 57-63 (2000).
44. Maack, T. et al. Physiological role of silent receptors of atrial natriuretic factor. Science 238, 675-678 (1987).